transmembrane protein 253Genealiases: C14orf176 · C14orf95 · NCRNA00220
Q-omics provides the consensus-scored TMEM253 profile across patient tissues and cancer cell-line models. TMEM253 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TMEM253 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, TMEM253 RNA expression shows 17,945 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, COAD, and THYM as cancer lineages where TMEM253 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM253 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM253 survival associations across molecular data types. TMEM253 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM253 RNA expression–survival associations across cancer types. High TMEM253 expression shows unfavorable associations in LUAD, ACC and HNSC, but favorable associations in BRCA, MESO and SCLC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for TMEM253 RNA expression.
This table summarizes TMEM253 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM253. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM253 shows lower tumor expression in COAD, THCA and READ and higher tumor expression in KIRP, LIHC and KIRC. The COAD box plot shows higher TMEM253 RNA expression in normal versus tumor tissue (log2 FC = −2.699, t-test p < 0.001).
This table shows molecular features associated with TMEM253 in patient tissues and cancer cell lines. In patient samples, TMEM253 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM253 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
